Disease Domain | Count |
---|---|
Neoplasms | 11 |
Endocrinology and Metabolic Disease | 3 |
Infectious Diseases | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic radiopharmaceuticals | 5 |
Unknown | 4 |
Peptide Conjugate Radionuclide | 2 |
Small molecule drug | 2 |
Diagnostic radiopharmaceuticals | 2 |
Target |
Mechanism RABV-G inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date25 Jan 2022 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RABV-G inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Jun 2022 |
Sponsor / Collaborator |
Start Date17 Jun 2021 |
Sponsor / Collaborator |
Start Date01 Oct 2008 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
99m Tc-glucarate(Molecular Targeting Technologies, Inc.) | Heart Injuries More | Phase 3 |
Rabies mAB(Molecular Targeting Technologies, Inc.) ( RABV-G ) | Rabies More | Phase 3 |
Nca 177 Lu-EBTATE ( SSTR2 ) | Thyroid Cancer, Hurthle Cell More | Phase 2 Clinical |
BPRDP056(Molecular Targeting Technologies, Inc.) ( Phosphatidylserine ) | Neoplasms More | Phase 1 |
TDURA(Molecular Targeting Technologies, Inc.) | Colorectal Cancer More | Phase 1 |